Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 52-60

  Astermark, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Genotype; Haemophilia; Inhibitors; Risk factors

Indexed keywords

ALLOANTIBODY; ANTIIDIOTYPIC ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR ANTIBODY; BLOOD CLOTTING FACTOR CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTIBODY PRODUCTION; BOLUS INJECTION; CONTINUOUS INFUSION; DRUG INTERMITTENT THERAPY; ENVIRONMENTAL FACTOR; GENE MUTATION; HEMOPHILIA; HEREDITY; HUMAN; IMMUNE RESPONSE GENE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR IX; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; ISOANTIBODIES; MALE; RISK FACTORS;

EID: 33646140127     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01261.x     Document Type: Review

References (62)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
2. Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
3. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
4. Lollar P. Pathogenic antibodies to coagulation factors. Part one: Factor VIII and IX. J Thromb Haemost 2004; 2: 1082-95.
5. Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 2002; 28: 273-6.
6. Singer ST, Addiego JE Jr, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
7. Reding MT, Wu H, Krampf M et al. Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
8. Wu H, Reding M, Qian J et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
9. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
10. Sasgary M, Ahmad RU, Schwarz HP, Turecek PL, Reipert BM. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
11. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-75.
12. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 1: 1777-84.
13. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation FVIII. J Thromb Haemost 2004; 2: 1385-94.
14. Hu GL, Okita DK, Conti-Fine BM. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects. J Thromb Haemost 2004; 2: 1908-17.
15. Judge TA, Tang A, Turka LA. Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 1996; 15: 38-49.
16. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
17. Hausl C, Ahmad RU, Schwarz HP et al. Preventing restimulation of memory B cells in hemophilia A: A potential new strategy for the treatment of antibody-dependent immune disorders. Blood 2004; 104: 115-22. [Epub 2004 Mar 4].
18. Qian J, Burkly LC, Smith EP et al. Role of CD154 in the secondary immune response: The reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
19. Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2001; 86: 1345-52.
20. Ewenstein BM, Hoots WK, Lusher JM et al. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85 (Suppl.): 35-9.
21. Hu GL, Okita DK, Diethelm-Okita BM, Conti-fine BM. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003; 1: 2159-66.
22. Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992; 89: 3795-9.
23. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-505.
24. Moreau A, Lacroix-Desmazes S, Stieltjes N et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000; 95: 3435-41.
25. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
26. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500-4.
27. Astermark J, Berntorp E, White GC, Kroner BL; MIBS Study Group. The Malmö International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
28. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
29. Oldenburg J, Schröder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41 (Suppl. 1): 82-8.
30. Schwaab R, Brackman HH, Meyer C et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
31. Tuddenhamn EGD, Mcvey JH. Genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-5.
32. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94 (Suppl. 1): 49-52.
33. Young M, Inaba H, Hoyer LW, Higuchi M, Kazazian HH Jr, Antonarakis SE. Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene. Am J Hum Genet 1997; 60: 565-73.
34. Oldenburg J, Schroder J, Schmitt C, Brackmann HH, Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 1998; 79: 452-3.
35. Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E; Malmo International Brother Study Group. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
36. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert A-K. Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, in press [Epub 2005 Dec 27].
37. Lalani I, Bhol K, Ahmed AR. Interleukin-10: Biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol 1997; 79: 469-83.
38. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-44.
39. Huang D, Zhou Y, Xia SQ, Pirskanen R, Liu L, Lefvert AK. Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications on diverse effects of IL-10 in the pathogenesis of the disease. J Neuroimmunol 1999; 94: 82-7.
40. Carroll MC, Katzman P, Alicot EM et al. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci USA 1987; 84: 8535-9.
41. Hay CR, Ollier W, Pepper L et al. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
42. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpsom E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
43. Lozier JN, Tayebi N, Zhang P. Mapping of genes that control the antibody response to human factor IX in mice. Blood 2005; 105: 1029-35. [Epub 2004 Sep 21].
44. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. A bi-allelic polymorphism at -308 in the promoter region of the TNF- α gene influences the risk of inhibitor development in patients with hemophilia A. Abstract WFH Congress Vancouver 2006.
45. Jacquemin M, Vantomme V, Buhot C et al. CD4+ T-cell clones specific for wild-type factor VIII: A molecular mechanism responsible for the higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
46. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1: 353.
47. Bouma G, Crusius JB, Oudkerk Pool M et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 456-63.
48. Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999; 94: 165-71.
49. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
50. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
51. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-9.
52. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
53. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
54. von Auer CH, Oldenburg J, von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann NY Acad Sci 2005; 1051: 498-505.
55. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
56. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
57. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
58. Goudemand J, Rothschild C, Demiguel V et al. FVIII-LFB and Recombinant FVIII Study Groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51. [Epub 2005 Sep 15].
59. Kreuz W, Ettingshausen CE, Auerswald G et al. GTH PUP Study Group. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88 (Suppl. 9): 17-20.
60. Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: A possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84: 2021-30.
61. Astermark J, Ekman M, Berntorp E. No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: A study of plasma-derived and recombinant products. Br J Haematol 1997; 99: 289-94.
62. Grosset AB, McGregor JR, Samlowski WE, Rodgers GM. Immunosuppressive effects of factor IX products: An in vitro study. Haemophilia 1999; 5:416-25.